

Date of preparation: 22 February 2024

Issuer's abbreviated name: SYNEKTIK SA

Current report: 12/2024 ESPI

Subject: Information on the conclusion of a significant sales agreement

Legal basis: Article 17(1) of the Market Abuse Regulation – inside information

Body of the report:

Time of publication: 1:56 p.m.

The Management Board of Synektik SA (Company) reports that the Company has learned that its subsidiary doing business as SYNEKTIK Czech Republic, s.r.o. with its registered office in Prague, Czech Republic concluded a significant agreement with the F.D. Roosevelt University Hospital in Banská Bystrica (Fakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica, Sídlo Nám. L. Svobodu 1, 975 17 Banská Bystrica), Slovakia (Hospital).

The agreement pertains to on-going supplies of instruments and accessories to be used by the Hospital's da Vinci minimally invasive surgery robotic system.

This agreement was concluded as a result of the procedure conducted in accordance with Slovakian public procurement law, and its maximum net value is EUR 5,976,546.00. This agreement has been concluded for a period of 4 years or until the maximum value of the purchase orders under the agreement is reached, whichever occurs first.

The other clauses do not deviate from the standards generally used in contracts of this type.

The signing of this agreement has been deemed to be significant by the Management Board of Synektik SA since its maximum net value exceeds 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual



reporting standards. The revenue generated on executing the da Vinci system delivery may affect the sales results in the 2023-2026 financial years.

Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board